THE SYMBOL “[****]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED AMENDMENT NO. 1 TO...Exclusive Commercialization Agreement • May 15th, 2019 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This Amendment No.1 to Exclusive Commercialization Agreement is made effective as of August 24, 2018 by and between RedHill Biopharma Ltd. (“RedHill”) and Concordia Pharmaceuticals Inc., by way of its Barbados branch (“Concordia”).
THE SYMBOL "[****]" DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMIITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION AMENDMENT NO. 1 TO EXCLUSIVE...Exclusive Commercialization Agreement • February 26th, 2019 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This Amendment No.1 to Exclusive Commercialization Agreement is made effective as of August 24, 2018 by and between RedHill Biopharma Ltd. (“RedHill”) and Concordia Pharmaceuticals Inc., by way of its Barbados branch (“Concordia”).
EXCLUSIVE COMMERCIALIZATION AGREEMENTExclusive Commercialization Agreement • February 22nd, 2018 • RedHill Biopharma Ltd. • Pharmaceutical preparations • Delaware
THIS EXCLUSIVE COMMERCIALIZATION AGREEMENT is made and entered into as of August 16, 2017 (the “Effective Date”), by and between ParaPRO LLC, an Indiana company, having a place of business at 11550 North Meridian Street, Suite 290, Carmel, Indiana 46032, USA and all Affiliates thereof (“ParaPRO”) and RedHill Biopharma, Inc. a Delaware corporation, having an address at 8045 Arco Corporate Drive, Suite 120, Raleigh, North Carolina 27617 and all Affiliates thereof (“RedHill”). RedHill and ParaPRO each may be referred to herein individually as a “Party,” or collectively as the “Parties”.
strictly confidential - EXECUTION VERSION THE SYMBOL "[****]" DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMIITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE...Exclusive Commercialization Agreement • February 23rd, 2017 • RedHill Biopharma Ltd. • Pharmaceutical preparations • New York
THIS EXCLUSIVE COMMERCIALIZATION AGREEMENT (the “Agreement”) is made and entered into as of December 30, 2016 (the “Effective Date”), by and between CONCORDIA PHARMACEUTICALS INC., a société à responsabilité limitée (private limited liability company) duly continued and validly existing under the laws of the Grand-Duchy of Luxembourg, having its registered office at 8-10 Avenue de la Gare – L-1610 Luxembourg, Grand-Duchy of Luxembourg, and registered with the Registre de commerce et des sociétés, Luxembourg (register of trade and companies) under number B 200 344, by way of its Barbados branch, carrying on business at 5 Canewood Business Centre, St. Michael, Barbados, BB 11005 (“Concordia”) and REDHILL BIOPHARMA LTD., an Israeli company, having a place of business at 21 Ha'arba'a Street, Tel-Aviv, Israel (“RedHill”). RedHill and Concordia each may be referred to herein individually as a “Party,” or collectively as the “Parties”.
